Bravelle

Bravelle is a brand name for a medication known as urofollitropin, which is a purified form of follicle-stimulating hormone (FSH). It is used in the treatment of infertility in women. Bravelle is administered via injection and is often used in conjunction with other fertility treatments such as in vitro fertilization (IVF).

Medical Uses

Bravelle is primarily used to stimulate the development of multiple follicles in women undergoing assisted reproductive technologies (ART). It is indicated for:

• Women who are undergoing ovulation induction.
• Women who are undergoing controlled ovarian hyperstimulation as part of an IVF cycle.

Mechanism of Action

Bravelle works by mimicking the action of naturally occurring FSH, a hormone involved in the growth and maturation of ovarian follicles. By stimulating the ovaries, Bravelle helps to produce multiple eggs, which can then be harvested for use in ART procedures.

Administration

Bravelle is administered via subcutaneous or intramuscular injection. The dosage and duration of treatment depend on the individual's response to the medication, which is monitored through regular ultrasound examinations and blood tests to measure estradiol levels.

Side Effects

Common side effects of Bravelle include:

• Ovarian hyperstimulation syndrome (OHSS)
• Abdominal pain
• Nausea
• Headache
• Injection site reactions

Contraindications

Bravelle should not be used in individuals with:

• Primary ovarian failure
• Uncontrolled thyroid or adrenal dysfunction
• Tumors of the pituitary gland or hypothalamus
• Abnormal uterine bleeding of undetermined origin

Related Pages

• Infertility
• Follicle-stimulating hormone
• In vitro fertilization
• Ovarian hyperstimulation syndrome
• Ovulation induction